Abstract
The present study reports on 15 patients with confirmed or suspected secondary fungal infection, who were treated with intravenous miconazole and a daily dose of 0.4 to 28 g (mean 9.8 g). The mycological findings confirmed infection with Aspergillus fumigatus in 6 patients and severe infection with Candida albicans in 4. Clinically mycological cures were achieved in 4 patients and some improvement was found in 3 others. The excellent patient tolerance of the drug makes it seem a likely treatment not only for patients with mycologically confirmed infection but also for those whose condition exposes them to a high risk of fungal infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
